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CRNDE is the gene symbol for Colorectal Neoplasia Differentially Expressed (non-protein-
coding), a long non-coding RNA (lncRNA) gene that expresses multiple splice variants and
displays a very tissue-specific pattern of expression. CRNDE was initially identified as a
lncRNA whose expression is highly elevated in colorectal cancer, but it is also upregulated
in many other solid tumors and in leukemias. Indeed, CRNDE is the most upregulated
lncRNA in gliomas and here, as in other cancers, it is associated with a “stemness” signa-
ture. CRNDE is expressed in specific regions within the human and mouse brain; the mouse
ortholog is high in induced pluripotent stem cells and increases further during neuronal dif-
ferentiation. We suggest that CRNDE is a multifunctional lncRNA whose different splice
forms provide specific functional scaffolds for regulatory complexes, such as the polycomb
repressive complex 2 (PRC2) and CoREST chromatin-modifying complexes, which CRNDE
helps pilot to target genes.
Keywords: CRNDE, lncRNA, IRX5, cancer, neurogenesis, 4933436C20Rik, multipotency, glioma
INTRODUCTION
GENE LOCUS AND TRANSCRIPTION
CRNDE is the gene symbol for Colorectal Neoplasia Differen-
tially Expressed (non-protein-coding), a human gene locus whose
expression was identified by our laboratory as upregulated in col-
orectal adenomas and carcinomas (Graham et al., 2011). CRNDE
is transcribed from chromosome 16 on the strand opposite to the
adjacent IRX5 gene, with which it may share a bidirectional pro-
moter. The locus produces transcripts with low coding potential,
which has resulted in its classification as a long non-coding RNA
(lncRNA; Cabili et al., 2011). CRNDE displays tissue-specific and
temporal expression patterns, in that it has little to no expression
in many normal adult tissues, such as colorectal mucosa, white
blood cells, and liver, while tissues with high CRNDE expression
include testis, breast, skin, parotid gland, and bronchial epithe-
lium (data from NextBio1, BioGPS2, and the UCSC Genome
Browser3). Expression levels in a selection of adult cell types
are shown in Figure 1A and expression of individual exons in
selected tissues at the bottom of Figure 2. CRNDE expression can
vary considerably within a tissue category, such as the different
types of adipose tissue or skeletal muscle (Figure 1A), as well as
within a particular organ. The brain is an example of a complex
organ that shows differential CRNDE expression within its var-
ious compartments and structures; it will be discussed in detail
below.
The CRNDE locus spans∼10 kb and comprises five core exons,
with an additional exon (E3) that is infrequently present in tran-
scripts (Figure 2A). Complex alternative splicing results in tran-
scripts that contain different combinations of exons, as well as
1http://www.nextbio.com
2http://www.biogps.org
3http://www.genome.ucsc.edu
varying amounts of retained intronic sequence (Graham et al.,
2011); many additional permutations have subsequently been
identified in our laboratory. A recent ENCODE survey found
that the efficiency of co-transcriptional splicing decreases pro-
gressively with proximity to the polyadenylation site and noted
that lncRNAs are especially prone to incomplete splicing (Tilgner
et al., 2012). Consistent with this, the retention of CRNDE intronic
segments seems mainly to involve the downstream introns, while
RNA-Seq profiling of the CRNDE locus (UCSC Genome Browser,
hg19 ENCODE RNA-Seq tracks) indicates that its upstream
introns – especially the first one – are removed efficiently.
Subcellular fractionation within HCT116 and HT29 CRNDE-
expressing colorectal cancer (CRC) cell lines revealed that tran-
scripts that have retained intronic sequence are highly enriched
in the nucleus (Ellis et al., 2012); typically, greater intronic reten-
tion results in higher nuclear enrichment. A nuclear localization
is in accordance with general findings for lncRNAs (Derrien et al.,
2012) and is consistent with their putative roles in transcriptional
regulation. Unexpectedly, we found that the fully spliced CRNDE
transcripts that contain only exon sequences are enriched in the
cytoplasm, a distribution typical of exonic protein-coding tran-
scripts. Evidence is emerging that some translation of CRNDE’s
short open reading frames (sORFs) is possible (see below).
A survey within the ENCODE project showed that the expres-
sion of almost 3% of lncRNAs shows high positive correlation with
that of a neighboring mRNA (Derrien et al., 2012). The CRNDE
promoter resides in the same CpG island as that of the adjacent
IRX5 gene, and the presumed promoter regions exhibit coordi-
nated methylation (Graham et al., 2011). We had also noticed
that some expression profile comparisons showed strongly con-
cordant differential expression of CRNDE and IRX5; for example,
CRNDE and IRX5 ranked first and third in the list of genes
differentially expressed in a comparison of subcutaneous with
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FIGURE 1 | Expression of CRNDE in normal adult human cell types. (A)
Expression levels were measured on Affymetrix HG-U133 arrays; data from
the Body Atlas, Cell Types, at http://www.nextbio.com. The median
expression across all 67 cell types in the database is shown by the green line.
All of the blood cells listed come from peripheral blood. (B) CRNDE
expression levels plotted against IRX5 expression levels for each cell type in
NextBio. An unreplicated experiment on dental odontoblasts with anomalous
outcomes for both genes has been omitted. When spermatozoa are excluded,
the two genes show correlated expression (R=0.72 in linear regression by
KaleidaGraph v3.6, Synergy Software).
visceral adipose tissue (VAT) depots (72- and 54-fold upregula-
tion, respectively; Wolfs et al., 2010). A survey of NextBio data for
normal human cell types showed that, in general, the expression
of CRNDE does indeed correlate positively (R= 0.72) with that
of IRX5 (Figure 1B). The striking exception to this relationship
occurs in spermatozoa, where CRNDE expression is very high but
IRX5 expression is very low; this may reflect a special role for
CRNDE in gametogenesis (discussed further below).
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FIGURE 2 | Human CRNDE gene locus. (A) Nucleotide numbering (top)
is for chromosome 16, hg19. Below that is the CRNDE locus, oriented 5′
to 3′ (left to right). Exons are shown as boxes with cyan fill; the most highly
conserved regions of the locus, which are intronic, are shown as boxes
with olive-green fill. The target regions of the two HG-U133 probesets are
shown immediately below the locus baseline. The two RefSeq genes are
shown; fully spliced AceView transcripts (not shown) typically commence
with just a short segment from the 3′ end of one of the two alternative
first exons, E1A and E1B. Evolutionary conservation within the locus is
shown for placental mammals (PhyloP) and for vertebrates in general
(Multiz alignments). The bottom of this panel shows the expression of
CRNDE exons and some intronic regions in normal human tissues,
obtained using the Affymetrix Exon Array 1.0; the data for each probeset
are color-coded (red, expression higher than the median value across all
tissues, green, expression lower than the median). Source of data below
locus diagram: UCSC Genome Browser (http://www.genome.ucsc.edu),
minus-strand display. (B) First exons of CRNDE and IRX5 and the
intervening promoter-containing region (∼2 kb) between their transcription
start sites. Transcription factor (TF) binding was identified from
“Transcription factor Binding Sites by ChIP-seq from ENCODE/HAIB”
tracks on UCSC Genome Browser. Regions of strongest binding in HCT116
cells by TFs (listed on the left) are shown by pink shaded boxes. Blue stars
indicate the locations of predicted strong TF DNA binding motifs, from the
TRANSFAC database (Wingender, 2008).
www.frontiersin.org November 2012 | Volume 3 | Article 270 | 3
Ellis et al. CRNDE expression: cancer and neurodevelopment
Recent data published as part of the ENCODE project have
included the mapping of genomic regions bound by specific tran-
scription factors (TFs) following immunoprecipitation of frag-
mented chromatin (TF-IP). This includes data on the CRNDE-
expressing CRC cell line HCT116 (data from Richard Myers’
laboratory; ENCODE Project Consortium et al., 2012). A repre-
sentation of regions and TFs showing the highest levels of binding
across the CRNDE-IRX5 promoter regions is shown in Figure 2B.
Strong binding of TFs is particularly evident in two regions, one
encompassing the CRNDE exon E1A and immediately upstream
of it, and a second region upstream of the IRX5 transcription start
site. As well as identifying sites of direct DNA binding by TFs, TF-
IP reveals sites where TFs do not bind directly to DNA but bind via
complexes with other TFs or chromatin components. In a number
of the examples shown in Figure 2B, direct binding can be inferred
from the presence of potential TF binding sequences within the
captured regions (e.g., ATF, CEBPB). Frequently, TF-IP demon-
strates binding of a specific TF to both the CRNDE and IRX5
promoter regions (e.g., ATF3, CEBPB, Max, and Sp1), supporting
the observation that the expression of both genes is under a level
of co-ordinate control (Figure 1B). While the survey of TF bind-
ing to the CRNDE-IRX5 promoter regions is necessarily limited, it
does indicate that their expression is subject to upstream signaling
pathways. ATF3 binding suggests responsiveness to CREB/ATF sig-
naling, while Fosl and JunD and SRF binding are associated with
response to serum components (via the MAP kinase pathway, for
example) and with cell cycle, growth, and differentiation. Binding
of the Myc partner protein, Max, also implicates CRNDE as a tar-
get of the Myc regulatory pathway. Of possible significance is the
binding to the CRNDE promoter of Sin3A and REST, which form
part of the CoREST complex; CRNDE RNA has been shown to
associate with CoREST (Khalil et al., 2009), perhaps indicating its
involvement in a cis-acting regulatory pathway.
Loci orthologous to CRNDE are identifiable in other verte-
brates. Curiously, the sequences in the CRNDE locus that are most
evolutionarily conserved fall within the introns rather than the
exons, and we have identified two genomic Vertebrate Conserved
(“gVC”) regions, one in Intron 1 (“gVC-In1”) and the other in
Intron 4 (“gVC-In4”). gVC-In1 and gVC-In4 are highly conserved
among vertebrates as far as the chicken,with gVC-In4 conservation
extending to Xenopus and zebrafish (Figure 2). The gVC-In4 core
extends over roughly 200–300 nucleotides and contains two con-
served secondary structures (EvoFold 72 and 76)4. Bioinformatic
analysis and our experimental data indicate that the gVC-In4 seg-
ment can be included within longer exon-containing transcripts,
but it may also be expressed independently. It therefore seems to
behave like both a transcribed ultraconserved region (“T-UCR”;
Calin et al., 2007) and an additional or alternative exon. Consid-
ering that the CRNDE locus as a whole is poorly conserved across
species, the role and function of gVC-In4, a predicted regulatory
element, are of particular interest.
Transcripts from genes homologous to human CRNDE are
found in many other mammals (e.g., chimpanzee, baboon, rhesus
macaque, cow, rat, mouse, and dog). In such transcripts, there is a
4http://www.cbse.ucsc.edu/~jsp/EvoFold
general tendency toward omission of E2 and E5 and the appending
of additional exons downstream of E6. This is true of the mouse
ortholog of CRNDE (gene symbol: 4933436C20Rik), which will
feature repeatedly in our review. For convenience we will refer to
it as “mouse CRNDE.” Clark et al. (2012) found that a transcript
from mouse CRNDE (there called “linc1399,” Table A1 in Appen-
dix) is notable for being very stable, with a half-life of 13.6 h;
only 51 of the 823 lncRNAs surveyed in their study had half-
lives >12 h. There is currently no information on the stability of
human CRNDE transcripts. While RNA longevity is consistent
with a function as a cellular housekeeper (Clark et al., 2012), we
find that CRNDE does not appear to behave as such.
CRNDE AS A lncRNA
As a newly identified gene, few publications address CRNDE’s
regulation and function directly; however, it features repeatedly
in the supplementary data of journal publications and in the
bioinformatics data in public repositories. Several lines of evi-
dence suggest that CRNDE exerts its effects primarily through its
RNA transcripts. First, bioinformatic analyses identified CRNDE
(under its various aliases, Table A1 in Appendix) as a putative
non-coding RNA. Its coding potential score is −1.85; the scores
for other lncRNA candidates range from −36 to +757 (Derrien
et al., 2012). Second, the study by Khalil et al. (2009) demonstrated
direct interaction between CRNDE transcripts and components
of the polycomb repressive complex 2 (PRC2) and CoREST com-
plexes. This study also found that there was an overlap in the
lists of genes affected by short interfering RNA (siRNA)-mediated
knockdown of CRNDE and PRC2,potentially implicating CRNDE
in the epigenetic remodeling of chromatin, and particularly in the
downregulation of gene expression via targeted histone methyla-
tion or demethylation by PRC2 or CoREST complexes, respectively
(Khalil et al., 2009). Third, comparative genomics reveals that the
features required for the translation of the most obvious of the
human sORFs (Graham et al., 2011), such as start/stop codons,
splice donors/acceptors, and reading frame integrity, are poorly
conserved in mammals more distantly related to us than chim-
panzee. Fourth, we have shown that the phenotypic effects asso-
ciated with the knock-in of the sORFs (Graham et al., 2011) into
CRC cell lines is unaffected by the deletion of their start codons
(Ellis et al., 2012), which indicates that the effects are mediated
by the transcripts rather than by any polypeptides that they may
encode. We have also been unable to achieve in vitro expression of
CRNDE polypeptides.
In the ENCODE project, a large-scale mass spectrometry sur-
vey found that human lncRNAs are rarely translated (Bánfai et al.,
2012). In contrast, a recent study by Ingolia et al. (2011) observed
that the majority of mouse lncRNAs contain regions of high
translation, with mouse CRNDE transcripts showing a low but
non-zero ribosome density. In addition, a specialized mass spec-
trometry survey by Granados et al. (2012) identified the CRNDE
peptide LQFIMELLY as being presented by the major histocom-
patibility complex 1 (MHC1) of Epstein–Barr virus-immortalized
B-lymphocytes. Granados et al. (2012) describe the immunopep-
tidome as arising from defective ribosomal products which do not
fold correctly. It is possible that the translation of CRNDE sORFs
is adventitious and that the polypeptides are unable to form stable
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folds, in which case all of the translated material would be avail-
able for presentation by the MHC1 complex. Altogether, despite
an awareness that fully spliced CRNDE transcripts accumulate in
the cytoplasm (Ellis et al., 2012) and that some translation of their
sORFs can occur (Granados et al., 2012), there is currently no evi-
dence that CRNDE polypeptides serve as important mediators of
the gene’s function.
CRNDE EXPRESSION IN CANCERS
COLORECTAL CANCER
We first identified CRNDE as a previously uncharacterized gene
locus (hCG_1815491, Table A1 in Appendix) that was differen-
tially expressed in colorectal neoplasia relative to normal colorec-
tal tissue, and in particular was among the most differentially
expressed genes in pre-cancerous adenomas (Graham et al., 2011).
Elevated CRNDE expression was also identified in independent
datasets of adenoma and CRC gene expression (Hong et al.,
2007; Sabates-Bellver et al., 2007; Kaneda et al., 2010; Nagaraj
and Reverter, 2011). Subsequently, our preliminary data from
knock-in of regions from CRNDE transcripts and from siRNA-
mediated knockdown studies of gVC-In4-containing transcripts
in CRC cells have indicated that CRNDE transcripts can promote
growth and suppress apoptosis (Ellis et al., 2012). This supports a
role for CRNDE as a mediator of oncogenesis.
OTHER CANCERS
Whereas we discovered CRNDE as a gene upregulated in colorec-
tal neoplasia, it is evident that CRNDE expression is increased
in a variety of other neoplastic diseases, especially cancers of the
blood and brain. Table 1 highlights a number of cancer types in
which CRNDE expression is significantly altered. These include
both solid tumors and leukemias. Interestingly, elevated CRNDE
expression is typically found in cancers that develop from a cell
type or organ in which it is not normally expressed (e.g., liver,
colon, kidney, leukocytes), suggesting that its presence gives the
tumor cell an advantage not normally required by that cell type. In
leukemias and some solid tumors, it is evident that altered CRNDE
expression is characteristic of different subclasses and may be asso-
ciated with different clinical outcomes. While moderately upregu-
lated in most acute myeloid leukemias (AML), CRNDE expression
is particularly elevated in FAB Type M2 AML (Le Dieu et al., 2009)
and in promyelocytic Type M3 AML (Payton et al., 2009). CRNDE
transcripts are among those whose expression is most elevated (21-
fold relative to non-cancerous tissue) in hepatocellular carcinoma
(HCC), with a greater increase (35-fold) in the HCC subset corre-
lating with high JNK1 activity. While CRNDE expression is mildly
elevated in prostate cancer (Lapointe et al., 2004; Pressinotti et al.,
2009), the upregulation is associated with a subgroup of prostate
cancers with poor prognosis, and about one-third of metastases
express CRNDE at elevated levels (Taylor et al., 2010; Markert et al.,
2011).
While CRNDE expression is most often elevated in cancers, in
some cases it is lower than in normal control tissue. For example,
in contrast to clear cell carcinomas and Type I papillary tumors of
the kidney, chromophobe tumors and oncocytomas show signifi-
cantly downregulated expression of CRNDE (Table 1). For serous
ovarian carcinoma, significantly decreased expression (10- to 54-
fold) relative to normal ovarian epithelium has been observed
(King et al., 2011; Shahab et al., 2011), and levels differ markedly
between different sub-types of ovarian cancer (Mateescu et al.,
2011; GSE26193)5. Some tumors with low CRNDE may simply
represent cases where the cell type of origin expresses little CRNDE
and it does not increase with neoplasia.
While de-regulated CRNDE expression – and particularly ele-
vated expression – is common to many cancers, we have little
understanding of whether its upregulation confers an oncogenic
phenotype, as it potentially does in CRC. For many of the pub-
lished studies from which we have drawn data, the detection
of expression is based on just two probesets in the Affymetrix
HG-U133 arrays. Of these, the first (238021_s_at) targets the 3′-
terminal exon, E6, and thus detects almost all of the canonical
AceView-listed CRNDE transcripts, almost all of which include
E6 (aAug10-lAug10)6. The second probeset (238022_at) detects
fully spliced transcripts across exons E2, E4, E5, and E6, and
therefore detects only a specific subset of CRNDE exonic tran-
scripts. There are often large differences in the extent of differential
expression displayed by each probe: between normal and can-
cer samples, the E6 probeset signal typically differs more. As
mentioned above, we know of many unspliced, nuclear-enriched
CRNDE transcripts which would only be detected by the E6
probeset. If this category is more elevated in cancer, it would
suggest a link between the CRNDE transcripts that interact with
chromatin-modifying complexes in the nucleus and those that
are most correlated with tumorigenesis. Given the complex reper-
toire of splice variants of CRNDE, it will be important to iden-
tify/characterize in more detail the transcript profile in differ-
ent cancer types. Unfortunately, probes for CRNDE transcripts
were not included in the GENCODE v3c lncRNA microarray
(Agilent) designed by the ENCODE consortium (Derrien et al.,
2012).
CRNDE EXPRESSION IN DEVELOPMENT
MULTIPOTENCY
CRNDE expression appears highest in the early stages of human
development and progressively decreases thereafter, with detected
expression ranking as follows (transcripts per million in paren-
theses): embryoid body (42)> fetus (25)> juvenile (17)> adult
(6) (UniGene EST database)7. The tentative link between CRNDE
expression and less specialized cell types has recently received some
very direct support, with mouse CRNDE being implicated as one
of several lncRNAs required for the maintenance of pluripotency
in mouse embryonic stem cells (moESC), and thus potentially
involved in tumorigenesis (Guttman et al., 2011). Specifically, at
the locus for mouse CRNDE (“linc 1399,” Table A1 in Appen-
dix), the promoter was bound by select pluripotency-related TFs,
including c-Myc and n-Myc, while knockdown of CRNDE was
associated with decreased levels of a different suite of critical
pluripotency markers: Sox2, Klf4, Nanog, and Oct4.
5http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193
6http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&term=
crnde&submit=Go
7http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.237396
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Table 1 | CRNDE expression in different cancers.
Cancer Fold change Reference
Colorectal cancer Adenomas 4.6, 41, 14.2 Graham et al. (2011), Nagaraj and Reverter
(2011), Sabates-Bellver et al. (2007)
Cancer 6.1, 16.1 Graham et al. (2011), Nagaraj and Reverter (2011)
Hepatocellular carcinoma Upregulated compared to matched normal liver 21 Chang et al. (2009)
Kidney Clear cell carcinoma vs. matched normal 2.3–5.95 Cifola et al. (2008), Gumz et al. (2007), Ooi et al.
(2011), Kort et al. (2008)
Type 1 papillary renal tumor 3.4, 4.6 Ooi et al. (2011), Kort et al. (2008)
Chromophobe renal tumor −7.9, −4.2, −6.4 Ooi et al. (2011), Kort et al. (2008), Yusenko et al.
(2009)
Oncocytoma −5.5, −5.6 Kort et al. (2008), Yusenko et al. (2009)
Adrenal Adrenocortical carcinoma vs. normal adrenal cortex 5.7 Giordano et al. (2009)
Pancreatic cancer Pancreatic cancer vs. matched normal tissue 2.9, 4.2, 5.4 Ishikawa et al. (2005), Pei et al. (2009), Donahue
et al. (2012)
Prostate cancer Mildly upregulated 1.3, 1.6 Pressinotti et al. (2009), Lapointe et al. (2004)
Associated with progression Markert et al. (2011), Taylor et al. (2010)
Ovarian cancer Serous ovarian tumors or tumor epithelial cells
compared to normal
−10 to −54 Shahab et al. (2011), King et al. (2011)
AML CRNDE is one of 731 genes whose expression
forms an AML signature
5.5–5.8 Rager and Fry (2012)
CD4(+) or CD8(+) T-cells of FAB type M2 AML
patients compared with normal cells
44–55 Le Dieu et al. (2009)
Acute promyelocytic
leukemia
AML M3 subtype. Bone marrow compared with
healthy marrow [CD34(+) cells, promyelocytes or
neutrophils]
10.2–89 Payton et al. (2009)
Multiple myeloma (MM) CRNDE probesets are the fourth and tenth most
upregulated in one novel cluster, characterized by
overexpression of cancer/testis antigens without
overexpression of proliferation genes
4.2–4.8 Broyl et al. (2010)
Part of a “spike” gene set associated with specific
translocation in MM
Kassambara et al. (2012)
T-cell leukemia CD4(+) T-cells from adult T-cell leukemia, compared
to normal
32 Choi et al. (2007)
Bone marrow of T-cell acute lymphoblastic
leukemia relative to normal
15 Kohlmann et al. (2008)
Cutaneous anaplastic large
cell lymphoma (ALCL)
ALCL relative to range of T-cell controls (tonsil and
peripheral blood)
55–62 Eckerle et al. (2009)
Gliomas Average across different glioma types and grades
relative to non-tumoral brain tissue controls
14–32 Zhang et al. (2012)
Guil et al. (2012) have shown that intronic segments from
several lncRNAs bind to PRC2 and recruit the complex to their
genes of origin, which then undergo epigenetic downregulation.
Although a direct association between CRNDE transcripts and
PRC2 has not been detected in moESC (Zhao et al., 2010), both
PRC1 and PRC2 bind to and down-regulate transcription from the
CRNDE promoter in such cells (Boyer et al., 2006; Endoh et al.,
2008; Pasini et al., 2008). The hESC cell line H1 also has relatively
low levels of CRNDE expression (Derrien et al., 2012). A nega-
tive feedback loop directed by CRNDE intronic sequences could
account for these observations.
Consistent with a function in cell pluripotency and/or an
undifferentiated state, as suggested in the study by Guttman
et al. (2011), T-cells exhibit a progressive decrease in CRNDE
levels during progression from the intrathymic T progenitor
stage to naïve T-cells; specifically, they drop after the transition
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from CD4(+)CD8(+) double-positive to CD4(+)CD8(−) single-
positive T-cells (Lee et al., 2004; GDS786). The dramatic increase
in CRNDE (44- to 55-fold) in both CD4(+) and CD8(+) cells of
AML patients (Le Dieu et al., 2009) suggests that loss of CRNDE
expression may correlate with the transition to a single-positive
stage rather than with selection of CD4(+) over CD8(+). Sus-
tained CRNDE expression during T-cell maturation may impede
the cell’s proper differentiation into single-positive cells, perhaps
forcing it to remain as a multipotent progenitor cell. The extent
to which CRNDE is elevated in blood cancers is quite remark-
able, and is consistent with an activation of stem or progenitor cell
expression programs in cancers (Table 1). This is also evident in
prostate cancer, where elevated CRNDE expression forms part of
a stem cell-like gene signature associated with a subset of more
aggressive cancers (Markert et al., 2011).
The complexity of developmental regulation is underscored
by a counter-example in which CRNDE expression is persistently
downregulated following telomerase-induced immortalization of
human urothelial cells (Chapman et al., 2008). One might have
expected CRNDE to rise in these cells, which are less able to differ-
entiate, but instead its expression is attenuated. A number of genes
involved in differentiation also showed decreased expression, rais-
ing the possibility that – in specific cellular contexts – CRNDE
transcripts might also participate in differentiation processes.
DIFFERENTIATION
In addition to an apparent role for CRNDE in maintenance of
cell pluripotency, several studies implicate CRNDE as impor-
tant in cellular differentiation. During differentiation, CRNDE
expression may be silenced or – depending upon the specific
lineage – may persist or increase, suggesting a potential role in
lineage determination. For example, Lin et al. (2011) observed
CRNDE to be one of the most highly expressed lncRNAs in
human induced pluripotent stem cells (iPSCs), but even more
importantly, to be one of the genes most highly induced during
their subsequent differentiation into neurons (Lin et al., 2011).
This work will be considered further below. Consistent with these
findings, CRNDE expression is also elevated (relative to human
embryonic stem cells, hESC) following induction into multipotent
mesodermal progenitor CD326(-)/CD56(+) cells using activin A,
bone morphogenetic protein 4, vascular endothelial growth factor,
and fibroblast growth factor 2 (Evseenko et al., 2010; E-GEOD-
21668)8. Other progenitor cell types also show elevated CRNDE
expression with differentiation. CD34+ hematopoietic progeni-
tor cells that were induced to differentiate using erythropoietin,
interleukin-3, and stem cell factor showed a 6.1-fold increase in
CRNDE levels from days 1 to 11 (Keller et al., 2006; GDS2431)9.
Airway primary cells differentiating into polarized, pseudostrati-
fied epithelia demonstrated a small but progressive increase (∼2-
fold) in CRNDE expression over the 28-day experiment (Ross
et al., 2007; GDS2615)10. Preadipocytes from omental adipose tis-
sue, but not those from subcutaneous adipose tissue (SAT), show
very low expression of CRNDE, in a similar pattern to that of HOX
8http://www.ebi.ac.uk/gxa/experiment/E-GEOD-21668/ENSG00000245694
9http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS2431
10http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS2615
and IRX gene family members (including the IRX5 gene adja-
cent to CRNDE), but CRNDE expression is markedly upregulated
in differentiated omental adipocytes (∼10-fold; Tchkonia et al.,
2007). Altogether, the evidence suggests that high CRNDE expres-
sion is associated with pluripotency, but that further increases
may accompany the process of differentiation into specific lin-
eages. It is therefore tempting to speculate that certain CRNDE
transcripts maintain pluripotency, while others specify cell lineage
and orchestrate progression of the cell toward that destination.
Beyond the findings of Tchkonia et al. (2007), there is an appar-
ent difference in overall CRNDE expression between VAT and SAT.
For example, Wolfs et al. (2010) identified CRNDE as the top dif-
ferentially expressed gene in SAT relative to omental VAT, with a
72-fold increase in the former. It was observed in both adipose tis-
sue studies that genes whose expression is favored in subcutaneous
adipocytes, including members of theHOX and IRX families, tend
to correlate with ectoderm development pathways, while genes
expressed in VAT represent those of mesoderm development. The
higher expression of CRNDE in SAT relative to omental VAT is
consistent with a general trend we have observed for substantial
CRNDE expression in normal adult tissues of ectodermal origin,
e.g., skin, breast, central nervous system (discussed below).
GAMETOGENESIS
In general, lncRNAs show relatively high expression in testicu-
lar tissue (Derrien et al., 2012), and CRNDE expression itself is
highest in the testes in both human and mouse (BioGPS, NextBio,
UCSC Genome Browser). CRNDE levels are 5.5-fold greater in
human testicular samples that contain spermatogonia compared
to those that contain no germ cells (von Kopylow et al., 2010). A
couple of independent studies reveal a rise in CRNDE expression
during the progression from murine spermatogonia (types A and
B), which are diploid, to secondary spermatocytes and spermatids,
which are haploid (and correspond to the meiotic and postmeiotic
stages, respectively; Namekawa et al., 2006; Chalmel et al., 2007). A
third study suggests that CRNDE expression decreases during the
progression from secondary spermatocytes to early (i.e., round)
spermatids (E-GEOD-21749). Altogether, it might be concluded
that CRNDE expression rises in the approach to meiosis, dur-
ing which it peaks, and remains high relative to other tissues at
the completion of spermatogenesis (spermatozoa, Figure 1A). In
view of its association with cancer, the high expression of CRNDE
in meiotic/postmeiotic sperm cells is noteworthy considering the
existence of a “cancer/testis antigen” (CTA) category of genes, a
correlation that implies connections between spermatogenesis and
somatic tumorigenesis (Fratta et al., 2011).
CRNDE IN NEUROBIOLOGY
EXPRESSION IN BRAIN
We have seen above that CRNDE is expressed during neural differ-
entiation from human iPSCs (Lin et al., 2011). Although this study
reported that CRNDE was detectable in fetal but not in adult nor-
mal brain tissue,we now know that CRNDE displays highly specific
spatial expression within the substructures of the mature human,
rat, and mouse brain; in this case, the adult brain samples came
from the pre-frontal cortex, where CRNDE expression is typically
low or absent. In the human brain, expression is predominant
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in the deep central structures, especially the basal ganglia and
adjacent structures (nucleus accumbens, globus pallidus, head of
caudate nucleus, putamen, thalamus, and corpus callosum), as well
as the cerebellum, posterior brain stem (midbrain, pons, medulla
oblongata), and spinal cord (Figure 3A). Like CRNDE, some lncR-
NAs involved in neurogenesis are expressed in fetal brain and in
the mature midbrain (substantia nigra) and cerebellum (Ng et al.,
2011).
The relative expression levels of CRNDE segments in some
types of human brain cells are shown in Figure 3B. Notably, exon
array data show that there is significant expression of sequences
within Intron 1; one of these probesets overlaps the conserved
FIGURE 3 | CRNDE expression in the human brain. (A) Schematic
showing the region where CRNDE is expressed in the adult human brain.
CRNDE expression (shaded pink) is concentrated in the deep central
structures (especially the basal ganglia and adjacent structures),
cerebellum, posterior brain stem, and spinal cord. In the
CRNDE-expressing region, no attempt has been made to display
differences in expression levels between or within structures.
(B) Affymetrix Human Exon 1.0 ST microarray expression data from the
late mid-fetal human brain, generated by the Sestan Lab at Yale University;
these are grouped by the median for each brain region and color-coded as
in Figure 2A. The first nine regions are from the neocortical region of the
cerebral cortex; PFC, pre-frontal cortex. Data sources:
http://www.molecularbrain.org, the Allen Human Brain Atlas (Brain
Explorer 2), and Sestan Human Brain Atlas (UCSC Genome Browser).
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gVC-In1 region. This region is not well expressed in other tis-
sues except for the testes (Figure 2A). From a comparison of
expression data for human, rat, and mouse brains, which have
been normalized to β2-microglobulin, it appears that there may
be higher expression of CRNDE in rodent than in human brains;
the maximum expression values detected for the three species were
5, 45, and 37, respectively (Table 2). The highest level recorded for
mouse brain is in the olfactory bulb (Table 2), the end of a tract
protruding from the CRNDE-expressing structures of the brain
(Figure 3A), which may be particularly important to rodents. Sig-
nificant expression has also been reported for some of the frontal
cortex of rodent brains, and for human frontal lobe gyri close
to the deep central structures and the olfactory tract (i.e., parts
of the orbital, paraterminal, and subcallosal gyri; not shown in
Figure 3A).
EXPRESSION IN BRAIN CANCERS
CRNDE expression is elevated in gliomas. This is particularly true
for glioblastomas (highest), astroblastomas, and astrocytomas,
whereas oligodendrogliomas and oligoastrocytomas show less dra-
matic differences (and in some cases none) from normal tissue
(Sun et al., 2006; Turkheimer et al., 2006; Murat et al., 2008; Pollard
et al., 2009; Paugh et al., 2010). In all tumor types, there tends to
be a positive correlation with grade and recurrence. Interestingly,
a recent study used publicly available Affymetrix HG-U133 array
Table 2 | Relative expression levels of CRNDE in brains of humans and
rodentsa.
MolecularBrain.orgb GeneNetwork.orgc
Human Ratd Mouse Mouse
First exon Last exon
Striatum – 8 31 10.6 9.7
→Caudate nucleus 0 – – – –
→Nucleus accumbens – 45 – –
Thalamus 4 – – – –
Hypothalamus 4 14 4 – –
Hippocampus 3 11 1 10.4 9.9
Olfactory bulb – – 37 – –
Amygdala 1 3 0 – –
Pineal – 24 – – –
Cerebellum 5 27 0 – –
Pituitary 1 1 1 – –
Spinal cord 5 9 2 – –
Frontal cortex 0 7 16 – –
aExpression microarray data from public databases. “–” denotes no data.
bValues from http:// www.molecularbrain.org, where expression is normalized to
β2-microglobulin.
cValues from http:// www.genenetwork.org for RMA-normalized Affymetrix exon
array probesets 5051610 and 5117873, which target the first and last exons of
the RefSeq gene, respectively; these are the two highest-expressing regions of
the locus. The lowest values (for an intronic probeset) were 5.7–5.8. Accession
number for striatum data is GN163, that for hippocampus is GN206.
dThe rat gene orthologous to CRNDE is RGD1565975.
data to profile lncRNA expression across different types and grades
of human gliomas. Of the 129 lncRNAs identified as differentially
expressed in gliomas, the results consistently and convincingly
identified CRNDE (both probesets) as the most highly upreg-
ulated lncRNA (32-fold; Zhang et al., 2012). This was the case
for low and high grade astrocytomas (15- and 36-fold, respec-
tively) and oligodendrogliomas (8- and 29-fold, respectively), and
CRNDE levels correlated positively with tumor grade in both
types. Along with CRNDE, HOTAIRM1 was also one of the most
upregulated lncRNAs in astrocytomas. Furthermore, CRNDE is
highly expressed in glioblastoma cell lines (LN229, LN215, LN319,
LN018, BS149) relative to normal brain (16- to 23-fold up) as well
as in primary glioblastomas (3.5- to 6.7-fold up; Grzmil et al.,
2011). Gliomas are unique in the degree of neovascularization
they exhibit, which allows for their invasion into surrounding
brain tissue, making surgical removal difficult. They also exhibit a
high degree of pluripotency, similar to that of stem cells (reviewed
by Watkins and Sontheimer, 2012), once again correlating high
CRNDE expression with stemness.
Another study revealed a positive correlation between CRNDE
levels and epidermal growth factor receptor (EGFR) gene amplifi-
cation, associated with EGFR overexpression, in high grade oligo-
dendrogliomas, a type of glioma in which CRNDE is not always
upregulated (Ducray et al., 2008). This study compared tumor
tissues with 1p19q codeletion vs. EGFR amplification, and found
that CRNDE expression was 37-fold higher in the latter and at lev-
els comparable to those seen in CRNDE-expressing gliomas (i.e.,
glioblastomas, astroblastomas, and astrocytomas); expression in
tumors with the codeletion was very low. The authors observed
parallels between genes expressed in 1p19q codeletion gliomas
and those in normal brain tissue. On the other hand, they note
that transcriptomic signatures induced by EGFR overexpression
mimic those of glioblastoma stem cells. In support of this, EGFR
expression inversely relates to responsiveness of the tumor to dif-
ferentiation stimulants (Hoi Sang et al., 1995).EGFR amplification
therefore is associated with maintenance of or reversion to a mul-
tipotent state. The intriguing relationship between CRNDE and
EGFR overexpression, and potentially cell potency/differentiation,
may extend to and have ramifications in other cancers. CRNDE’s
participation in various signaling pathways is currently being
investigated in our laboratory.
INVOLVEMENT IN NEURAL DEVELOPMENT
Brain development and neural differentiation are complex
processes that rely upon epigenetic changes. These involve both
histone modifications and DNA methylation. DNA methylation
is believed to play a role in neural stem cell (NSC) differenti-
ation into neurons or glial cells, such as astrocytes and oligo-
dendrocytes, as well as in glioma formation. Neurogenesis gives
rise to NSC, which in early gestation only have the potential
to become neurons, but in late gestation gain the potential to
become astrocytes and oligodendrocytes (Qian et al., 2000). One
example of DNA methylation-induced regulation of neurogen-
esis involves IL-6 signaling in astrocyte specification of NSC.
During gestation, DNA methylation determines whether NSC
develop into neurons or astrocytes (Takizawa et al., 2001). In
late gestation, IL-6-induced demethylation of STAT3 binding
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sites within promoters of genes specifying astrocyte differentia-
tion allows for binding by the STAT3 TF, which transactivates
genes necessary for astrocyte formation (Takizawa et al., 2001;
Hatada et al., 2008). Methylation of these promoters appears to
be a key regulatory step in neuronal vs. astrocyte specification
as it prevents STAT3 binding even when the appropriate sig-
nals for astrocyte differentiation are available (Namihira et al.,
2008).
Histone modifications are also important for maintenance of
stem cell pluripotency and glioma cell proliferation (Suvà et al.,
2009; Orzan et al., 2011). HDAC inhibition has been shown to
induce neuronal over oligodendrocyte differentiation by revert-
ing the cell from an oligodendrocyte-specific fate toward neu-
ronal proclivity (reviewed by Namihira et al., 2008; Mercer et al.,
2010). As one example, HDAC1 and HDAC2 disrupt β-catenin-
TCF7L2 interaction, which is normally triggered by Wnt signaling
and linked with antagonism of oligodendrocyte differentiation.
HDACs compete with β-catenin for binding to TCF7L2, and
cause the transcription of genes that induce oligodendrocyte
differentiation (Ye et al., 2009).
Many examples now exist for the association of lncRNAs with
chromatin-modifying complexes such as the PRC2 complex, or
with specific TFs. From this work, a picture is emerging that lncR-
NAs are key mediators of epigenetic programming through the
targeting of such complexes to specific chromosomal sites. Expres-
sion of lncRNAs in the brain is highly specific, both spatially
and temporally, and it is proposed that they are key regulators
of neural differentiation (Qureshi et al., 2010). This is supported
by studies that directly implicate specific lncRNAs (e.g., MALAT1,
Evf2) in the promotion of neuronal differentiation and that show
the expression of lncRNAs during the glial/neuronal specifica-
tion stage of development (Bond et al., 2009; Bernard et al., 2010;
Mercer et al., 2010).
Similar to the Guttman et al. (2011) study in moESC, Ng
et al. (2011) recently performed a global study in hESC to inves-
tigate the lncRNAs necessary for pluripotency, as well as those
necessary for neuronal differentiation. Neurons induced to differ-
entiate from hESC showed differential expression of nearly one
thousand lncRNAs from those represented on their array (which
unfortunately did not include probes targeting CRNDE). Targeted
knockdown of different lncRNAs was shown to either induce
or prevent neuronal differentiation. The authors demonstrated
the interaction of these lncRNAs with chromatin-modifying pro-
teins such as SUZ12 (a subunit of PRC2) and REST (a bind-
ing partner for CoREST), which may mediate neuronal cell fate
specification. The paper demonstrates the likely role of multi-
ple lncRNAs in stem cell maintenance as well as neuronal dif-
ferentiation, and the potential involvement of PRC2 and CoR-
EST complexes, with which CRNDE RNA has been shown to
associate.
Though evidence of a functional role in human neurogenesis
is lacking, Lin et al. (2011) gave special mention to CRNDE as
one of the highest-expressing intergenic lncRNAs within iPSCs,
and one which furthermore exhibited one of the largest elevations
during neuronal differentiation. CRNDE expression (identified
by RNA deep sequencing and validated by quantitative PCR)
increased 4.3-fold over 10 days (the earliest time point measured)
following induction of neurogenesis. Similarly, Denis et al. (2011)
identified CRNDE as being upregulated in neural progenitor cells
(but not in mesenchymal progenitor cells) relative to hESC (2.5-
fold up). Lin et al. (2011) suggest that lncRNAs – including
CRNDE – are involved in the control of neural specification,
which raises the question of whether the absence of CRNDE dur-
ing differentiation might allow development into non-neuronal
lineages. Either way, we have shown above (Figure 1B) that
expression from the CRNDE locus is coordinated with that of
IRX5, which belongs to a gene family involved in brain pattern-
ing and neurogenesis (Cohen et al., 2000; Anselme et al., 2007).
Both CRNDE and IRX5 are highly expressed in the thalamus and
cerebellum relative to other brain regions (Sestan Human Brain
Atlas).
Evidence is also emerging that lncRNAs are involved in the
development of specialized neural tissues such as the retina of the
eye. For example, in mouse, the lncRNA RNCR2 plays a critical role
in regulating mammalian retinal cell fate specification (Rapicavoli
et al., 2010), and the intergenic lncRNA TUG1 appears to favor
rod cell specification by inhibiting cone-specific gene expression
(Young et al., 2005). Mouse CRNDE is known to be expressed dur-
ing the development of a subset of cells in the neuroblastic layer
of the retina. Its expression has a narrow temporal window, and
shifts from inner to outer layer during development (Trimarchi
et al., 2007). Such precise and transient expression is consistent
with a defined regulatory function.
As discussed above, CRNDE is the most highly upregulated
lncRNA in gliomas. The origin of gliomas is a subject of debate, but
recent evidence suggests they derive from neural precursors/NSCs;
stem cells isolated from these tumors were capable of forming
gliomas, glial cells, and neurons, which accords with the capa-
bilities of NSCs (Watkins and Sontheimer, 2012). In any case, the
biology of glioma cells resembles that of NSC, in that both are mul-
tipotent and express similar stem cell markers (Bao et al., 2006).
CRNDE’s upregulation in glioma tumors may serve a similar pur-
pose as it does in neural precursors, i.e., to maintain the stemness
of the tumor cells. As long as CRNDE expression is maintained,
differentiation into glial cells would be impeded. Upregulation
of the EZH2 subunit of PRC2 (a complex with which CRNDE
RNA has been shown to associate) has been reported in gliomas,
especially glioblastomas, and appears necessary for maintenance
of glioblastoma stem cell pluripotency and glioma cell prolifer-
ation (Suvà et al., 2009; Orzan et al., 2011). Thus, epigenetic
modifications likely play a large part in neurogenesis and brain
tumorigenesis.
In summary, the highly specific pattern of CRNDE expres-
sion in brain tissue, its involvement in maintenance of stem-
ness, and its association with PRC2 and CoREST chromatin-
modifying complexes suggest that CRNDE may be involved in
lineage specification in the mammalian brain.
A POTENTIAL LINK TO NEURODEGENERATION
Non-coding RNAs, including some lncRNAs, are now proving to
be important contributors to neurodegenerative processes (Salta
and De Strooper, 2012). Of possible relevance to CRNDE is the
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review by Watkins and Sontheimer (2012) which provides an
interesting discussion of the similarities, mainly in the symp-
toms and end results, between neurodegenerative disease and
glial tumorigenesis. Neurodegeneration is a hallmark of gliomas
that is attributed to their characteristic infiltrative growth, which
kills existing neurons within surrounding brain tissue (Lee et al.,
2011; Watkins and Sontheimer, 2012). Neurodegeneration also
results from gliomas’ ability to release the neurotransmitter glu-
tamate, and their inability to clear glutamate from the synaptic
cleft due to the epigenetic silencing of its receptors. Overall, this
causes glutamate excitotoxicity, which in turn results in numerous
ramifications associated with both cancer and neurodegenera-
tive pathologies (Watkins and Sontheimer, 2012). As discussed
above, CRNDE is markedly elevated in gliomas and is thus asso-
ciated with a neurodegenerative process, albeit one resulting from
cancer.
There is little in the existing data to link the various neurode-
generative diseases with abnormal CRNDE expression. We have
examined CRNDE expression in a gene expression dataset focused
on Alzheimer’s disease (AD) and representing 1300 brain tissue
samples from 1000 people (Gene Logic, Gaithersburg, MD, USA).
AD affects not only the cerebral cortex, where (for the most part)
CRNDE is not normally expressed, but is characterized in the ear-
liest stages by degeneration of the hippocampus, a structure in or
near the CRNDE-expressing region (Figure 3). After correcting for
patient age and gender, no statistically significant correlation was
found between CRNDE expression and patient status in regard
to AD, neuritic amyloid plaques, or hippocampal neurofibrillary
tangles.
Several lncRNAs have been implicated in the hereditary neu-
rodegenerative disorder, Huntington’s disease (HD; Johnson,
2012). One study does show a modest positive correlation between
CRNDE expression and HD; this is especially noticeable in the cau-
date nucleus from patients with grade III HD (2.4-fold increase
relative to non-HD control tissue; Hodges et al., 2006). More-
over, an Ingenuity Pathway Analysis of our preliminary microarray
studies indicates “HD Signaling” as a highly affected canonical
pathway upon knockdown of CRNDE in a CRC cell line (unpub-
lished data). HD is characterized by expansion of the (CAG)n
repeat motif in the huntingtin gene, which yields a mutant protein.
Studies have also investigated the PRC2 complex in HD, and there
may be a correlation of wild-type and mutant huntingtin pro-
tein with PRC2 activity and H3K27 trimethylation (Seong et al.,
2010).
The possible association of CRNDE with HD suggests that it
may be rewarding to investigate the expression of its transcripts
in hereditary neurodegenerative conditions that involve cell types
and brain regions in which the gene is expressed.
CONCLUSION
Long non-coding RNAs are increasingly implicated in the molec-
ular mechanisms that underpin normal developmental processes,
such as cellular multipotency and differentiation, as well as in
the dysregulation that characterizes cancer and neurological dis-
orders (reviewed by Niland et al., 2012). CRNDE is a gene that
expresses multiple splice variants of a lncRNA and displays a
very time- and tissue-specific pattern of expression. It was ini-
tially identified as a gene whose expression is highly upregulated
in CRC, but it also increases in many other solid tumors and in
leukemias. Indeed, CRNDE is the most upregulated lncRNA in
gliomas and here, as in other cancers, it is associated with a “stem-
ness” signature. The rise in CRNDE levels during neoplasia may
be a response to perturbations in upstream signaling pathways,
for example the MAP kinase pathway, which among other actions
mediates SRF activity. Regulation by Myc may be a key compo-
nent of CRNDE expression in stem cells and its overexpression in
cancers such as gliomas and CRC, where elevated Myc expression
and (in the cancers) gene amplification are common. Cell culture
studies using bioactive agents (e.g., hormones, growth factors),
specific inhibitor compounds, and knock-in or knock down of
specific TFs may shed light on the signaling pathways that control
CRNDE expression.
Based on precedents with other lncRNAs (Tsai et al., 2010;
Niland et al., 2012), we suggest that CRNDE is a multifunctional
lncRNA whose different splice isoforms may provide specific func-
tional scaffolds for regulatory complexes, such as the PRC2 and
CoREST chromatin-modifying complexes, which they can pilot to
target genes. The promoters of these genes are then downregu-
lated by epigenetic modification. In ESC, CRNDE’s function may
be to suppress lineage-determining genes. During the differentia-
tion of certain lineages (e.g., ectodermal cell types), CRNDE levels
are known to rise further, perhaps in order to suppress genes that
specify alternate cell fates. In cancers of tissues where CRNDE is
not normally expressed, its aberrant elevation may again help to
suppress lineage markers and revert the cells to a less differentiated
state.
The importance of CRNDE to a complete organism can be
addressed using CRNDE knock-out mice, with the hope that
tissue-specific knock-outs will reveal much about CRNDE’s roles
in specialized processes such as gametogenesis and brain function.
In vitro, the examination of different cell lines in which CRNDE
has been knocked in or knocked down should continue to be
highly informative about its molecular interactions, with isoform-
specific studies helping to distinguish between effects mediated by
the exonic and intronic segments of the transcripts. Phenotypic
assays on these cells will illuminate the functional consequences
of adding or removing individual CRNDE transcripts. Expression
microarray surveys will reveal the scope of CRNDE’s target gene
set and how this varies between cell types, as well as the extent
to which differentiation/lineage markers are included. Established
methods such as FISH and new high-resolution methods, includ-
ing ChIRP (Chu et al., 2011) and CHART (Simon et al., 2011),
offer opportunities to determine the full complement of genomic
targets bound by CRNDE transcripts. Furthermore, related cap-
ture technologies will help to identify proteins not yet known to
bind to CRNDE transcripts.
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APPENDIX
Table A1 | Gene/transcript names and microarray probesets for human and mouse CRNDE.
Attribute Human Mouse
Details Context/source Details Context/source
GENE
Location/build (RefSeq gene) chr16:54,952,777-54,963,101 (NR_034105) NCBI GRCh37 chr8:94,879,820-
94,881,675
NCBI m37
chr16:54952778-54962690 (NR_034106) UCSC hg19 UCSC mm9
Ensembl 68.37 Ensembl v47
Strand Minus Minus
Gene symbol CRNDE 4933436C20Rik
Ensembl gene ENSG00000245694 ENSMUSG00000031736
UniGene Hs.237396 Mm.86664
Vega gene CRNDE RP24-69M8.2
H-InvDB 8.0 ID HIX0038716 (Cluster ID)
Locus tag hCG_1815491
Gene ID LOC643911+LOC388279 LOC626493
Other gene ID PNAS-108 AF275804 in GenBank 71296 Entrez GeneID
lncipedia gene lnc-IRX3-4 lncipedia.org
lncRNA
lincIRX5 Khalil et al. (2009) linc1399 Clark et al. (2012)
XLOC_011950 Cabili et al. (2011) linc1399 Guttman et al. (2011)
(Ensembl gene) Derrien et al. (2012) NR_033641 NCBI RefSeq
NR_034105 NCBI RefSeq (Graham
et al., 2011)NR_034106
LINC00180
NCRNA00180
MICROARRAY PROBESETS
Affymetrix GeneChip probeset IDs 238021_s_at Human Genome U133 1431297_a_at Mouse Genome 430
2.0238022_at
3692517-3692527 Human Exon 1.0 ST 27 non-
consecutivea
Mouse Exon 1.0
3692529, -31, -33
3661555, -56, -58
Agilent SurePrint G3 probeset IDs A_21_P0008884 Human Gene
Expression 8×60 K v2
A_51_P378381 Mouse Gene
Expression 8×60 KA_19_P00322533
A_32_P104063
A_19_P00322531
A_19_P00318645
Illumina expression BeadChips ILMN_1671800 HumanWG-6 3.0 ILMN_2604403 Sentrix Mouse 6.2
aThe 11 probesets that map to RefSeq exons are numbers 4333223, 4615448, 4907780, 4956596, 5051610, 5077062, 5117873, 5219245, 5259826, 5442877, and
5461263.
www.frontiersin.org November 2012 | Volume 3 | Article 270 | 15
